SRPT PE Ratio & Valuation,Is SRPT Overvalued

SRPT Relative Valuation

SRPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SRPT is overvalued; if below, it's undervalued.

Historical Valuation

Sarepta Therapeutics Inc (SRPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.48 is considered Undervalued compared with the five-year average of 4.42. The fair price of Sarepta Therapeutics Inc (SRPT) is between 922.20 to 998.60 according to relative valuation methord. Compared to the current price of 21.53 USD , Sarepta Therapeutics Inc is Undervalued By 97.67%.

Relative Value

Fair Zone

922.20-998.60

Current Price：21.53

97.67%

Undervalued

90.18

32.80

EV/EBITDA

Sarepta Therapeutics Inc. (SRPT) has a current EV/EBITDA of 32.80. The 5-year average EV/EBITDA is 3.04. The thresholds are as follows: Strongly Undervalued below -167.41, Undervalued between -167.41 and -82.18, Fairly Valued between 88.27 and -82.18, Overvalued between 88.27 and 173.50, and Strongly Overvalued above 173.50. The current Forward EV/EBITDA of 32.80 falls within the Historic Trend Line -Fairly Valued range.

55.47

EV/EBIT

Sarepta Therapeutics Inc. (SRPT) has a current EV/EBIT of 55.47. The 5-year average EV/EBIT is 6.61. The thresholds are as follows: Strongly Undervalued below -75.71, Undervalued between -75.71 and -34.55, Fairly Valued between 47.77 and -34.55, Overvalued between 47.77 and 88.93, and Strongly Overvalued above 88.93. The current Forward EV/EBIT of 55.47 falls within the Overvalued range.

1.48

Sarepta Therapeutics Inc. (SRPT) has a current PS of 1.48. The 5-year average PS is 6.70. The thresholds are as follows: Strongly Undervalued below 0.20, Undervalued between 0.20 and 3.45, Fairly Valued between 9.95 and 3.45, Overvalued between 9.95 and 13.20, and Strongly Overvalued above 13.20. The current Forward PS of 1.48 falls within the Undervalued range.

28.54

P/OCF

Sarepta Therapeutics Inc. (SRPT) has a current P/OCF of 28.54. The 5-year average P/OCF is -3.03. The thresholds are as follows: Strongly Undervalued below -361.46, Undervalued between -361.46 and -182.25, Fairly Valued between 176.19 and -182.25, Overvalued between 176.19 and 355.41, and Strongly Overvalued above 355.41. The current Forward P/OCF of 28.54 falls within the Historic Trend Line -Fairly Valued range.

23.44

P/FCF

Sarepta Therapeutics Inc. (SRPT) has a current P/FCF of 23.44. The 5-year average P/FCF is -132.62. The thresholds are as follows: Strongly Undervalued below -1352.56, Undervalued between -1352.56 and -742.59, Fairly Valued between 477.34 and -742.59, Overvalued between 477.34 and 1087.31, and Strongly Overvalued above 1087.31. The current Forward P/FCF of 23.44 falls within the Historic Trend Line -Fairly Valued range.

Sarepta Therapeutics Inc (SRPT) has a current Price-to-Book (P/B) ratio of 1.71. Compared to its 3-year average P/B ratio of 11.57 , the current P/B ratio is approximately -85.23% higher. Relative to its 5-year average P/B ratio of 11.82, the current P/B ratio is about -85.54% higher. Sarepta Therapeutics Inc (SRPT) has a Forward Free Cash Flow (FCF) yield of approximately -16.89%. Compared to its 3-year average FCF yield of -8.37%, the current FCF yield is approximately 101.86% lower. Relative to its 5-year average FCF yield of -7.74% , the current FCF yield is about 118.23% lower.

1.71

P/B

Median3y

11.57

Median5y

11.82

-16.89

FCF Yield

Median3y

-8.37

Median5y

-7.74

Competitors Valuation Multiple

The average P/S ratio for SRPT's competitors is 267.16, providing a benchmark for relative valuation. Sarepta Therapeutics Inc Corp (SRPT) exhibits a P/S ratio of 1.48, which is -99.45% above the industry average. Given its robust revenue growth of -14.52%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SRPT decreased by 82.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.02 to -7.77.

The secondary factor is the Revenue Growth, contributed -14.52%to the performance.

Overall, the performance of SRPT in the past 1 year is driven by P/E Change. Which is more unsustainable.

-14.52%

467.17M → 399.36M

Revenue Growth

-726.70%

7.19 → -45.06

Margin Expansion

658.93%

-1.02 → -7.77

P/E Change

-82.29%

121.59 → 21.53

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Sarepta Therapeutics Inc (SRPT) currently overvalued or undervalued?

What is Sarepta Therapeutics Inc (SRPT) fair value?

SRPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sarepta Therapeutics Inc (SRPT) is between 922.20 to 998.60 according to relative valuation methord.

How does SRPT's valuation metrics compare to the industry average?

What is the current P/B ratio for Sarepta Therapeutics Inc (SRPT) as of Dec 15 2025?

As of Dec 15 2025, Sarepta Therapeutics Inc (SRPT) has a P/B ratio of 1.71. This indicates that the market values SRPT at 1.71 times its book value.

What is the current FCF Yield for Sarepta Therapeutics Inc (SRPT) as of Dec 15 2025?

As of Dec 15 2025, Sarepta Therapeutics Inc (SRPT) has a FCF Yield of -16.89%. This means that for every dollar of Sarepta Therapeutics Inc’s market capitalization, the company generates -16.89 cents in free cash flow.

What is the current Forward P/E ratio for Sarepta Therapeutics Inc (SRPT) as of Dec 15 2025?

As of Dec 15 2025, Sarepta Therapeutics Inc (SRPT) has a Forward P/E ratio of 90.18. This means the market is willing to pay $90.18 for every dollar of Sarepta Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sarepta Therapeutics Inc (SRPT) as of Dec 15 2025?

As of Dec 15 2025, Sarepta Therapeutics Inc (SRPT) has a Forward P/S ratio of 1.48. This means the market is valuing SRPT at $1.48 for every dollar of expected revenue over the next 12 months.

SRPT Valuation